Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 0.54 |
| ▸ | PSEN2 | P49810 | 20/20 | 0.54 |
| ▸ | APH1B | Q8WW43 | 20/20 | 0.54 |
| ▸ | NCSTN | Q92542 | 20/20 | 0.54 |
| ▸ | APH1A | Q96BI3 | 20/20 | 0.54 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7923905 | 0.84 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1237313 | 0.84 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7827197 | 0.84 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15062288 | 0.84 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL297411 | 0.84 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7819827 | 0.84 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15943562 | 0.84 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL511511 | 0.84 | NR4A1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Hydrochloric Acid SCHEMBL16402312 | 0.83 | NR4A1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Hydrochloric Acid SCHEMBL2480936 | 0.83 | NR4A1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598437-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160304534-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2016-10-20 | — | — | US | disclosed |
| US-9096582-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP (US) | 2015-08-04 | — | — | US | disclosed |
| WO-2015084752-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015066697-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| US-20140296311-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2014-10-02 | — | — | US | disclosed |
| US-8809318-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8759337-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8580956-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8518975-B2 | Gamma secretase modulators | Merck Sharp + Dohme Corp. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20090270623-A1 | PROCESS FOR PRODUCTION OF CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270623-A1 | PROCESS FOR PRODUCTION OF CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009108766-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER ' S DISEASE | SCHERING CORPORATION (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| WO-2009076337-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008153792-A2 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304534-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 4/4885APH1B 9/4885 |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | APP, BACE1, PSEN1 | PSEN1 3/4885PSEN2 6/4885APH1B 11/4885 |
| US-20090270623-A1 | PROCESS FOR PRODUCTION OF CINNAMIDE DERIVATIVE | CBR1, H1-0, CBR3 | PSEN1 4651/4885PSEN2 4686/4885APH1B 3878/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | PSEN1 3275/4885PSEN2 3796/4885APH1B 2344/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | PSEN1 3/4885PSEN2 6/4885APH1B 11/4885 |
| US-20140296311-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 5/4885APH1B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.